This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

This study has been completed.
Information provided by (Responsible Party):
Xigen SA Identifier:
First received: September 5, 2014
Last updated: January 23, 2017
Last verified: January 2017
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.

Condition Intervention Phase
Inflammation Pain Cataract Drug: XG-102 Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation

Resource links provided by NLM:

Further study details as provided by Xigen SA:

Primary Outcome Measures:
  • Absence of anterior chamber cells for the 900µg XG-102 sub-conjunctival injection compared to vehicle [ Time Frame: Day 15 ]
  • Absence of pain for the 900µg XG-102 compared to vehicle [ Time Frame: Day2 ]

Secondary Outcome Measures:
  • Use of rescue medication [ Time Frame: up to Day 85 ]

Other Outcome Measures:
  • Specular microscopy [ Time Frame: Day 85 ]
  • Adverse event (AE) monitoring [ Time Frame: up to Day 85 ]

Enrollment: 339
Study Start Date: September 2014
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: XG-102 Drug: XG-102
Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Placebo Comparator: Placebo Drug: Placebo
comparison of XG-102 versus placebo sub-conjunctival injection efficacy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Have provided written informed consent, approved by the appropriate institutional review board;
  • Be greater than or equal to 18 years of age of either sex or any race;
  • Be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation in the study eye;
  • Have a pin-hole visual acuity (VA) < 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1;
  • (For females of childbearing potential) agree to have urine pregnancy testing performed at Visit 1 (must be negative) and at exit visit; must not be lactating; and must agree to use a medically acceptable form of birth control1 throughout the study duration. Women of childbearing potential include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).

Key Exclusion Criteria:

  • Have a known sensitivity or allergy to the class of medication of the active ingredient in the study medication or any of the study medication's components;
  • Have any intraocular inflammation (e.g., white blood cells or flare) present in the study eye at the Visit 1slit lamp examination;
  • Have a score greater than "0" on the Ocular Pain Assessment at Visit 1 or 2 in the study eye;
  • Have an immunosuppressive or an autoimmune disease that in the opinion of the Investigator could affect intraocular inflammation or the normal healing process of the eye;
  • Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;
  • Currently have suspected or known malignancy or be currently receiving antineoplastic therapy;
  • Be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration, or have a positive urine pregnancy test at Visit 1;
  • Use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics and other pain medications) or immunomodulating agents, systemically, or in either eye, and/or use medications for benign prostatic hyperplasia (BPH), from the washout period through the duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02235272

United States, California
Garden Grove, California, United States, 92843
Sponsors and Collaborators
Xigen SA
Principal Investigator: Steven M Silverstein, MD Silverstein Eye Centers
  More Information

Responsible Party: Xigen SA Identifier: NCT02235272     History of Changes
Other Study ID Numbers: SDD-1002-064
Study First Received: September 5, 2014
Last Updated: January 23, 2017

Additional relevant MeSH terms:
Pathologic Processes
Lens Diseases
Eye Diseases
Uveal Diseases processed this record on August 18, 2017